Peter Koefoed

Title: Peter Koefoed: Innovator in Vaccine Development

Introduction

Peter Koefoed, an accomplished inventor from Horsholm, Denmark, has made significant contributions to the field of vaccine development. With a total of two patents to his name, his work primarily focuses on novel methodologies and compositions that combat diseases associated with amyloid deposition.

Latest Patents

Koefoed's latest patents include the innovative "Amyloid-beta polypeptide vaccine," which discloses novel methods and compositions aimed at combating diseases characterized by the deposition of amyloid. These methods primarily involve immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). The patent emphasizes the administration of analogs of autologous APP or Aβ, designed to induce antibody production against the corresponding amyloidogenic polypeptides. A particularly preferred immunogen highlighted in this patent is autologous Aβ, modified to incorporate a few foreign, immunodominant and promiscuous T-cell epitopes. The patent also details methods for preparing these analogs, along with pharmaceutical formulations, nucleic acid fragments, vectors, transformed cells, and polypeptides.

Koefoed's second patent, titled "Synthetic vaccine agents," presents novel immunogens composed of an activated polyhydroxypolymer backbone, to which two separate antigenic determinants are attached. The first determinant includes a B-cell or cytotoxic T-lymphocyte (CTL) epitope, while the second includes a T-helper epitope. This dual-epitope approach allows for a robust immune response, and the patent discloses exemplary immunogens that utilize a linear tresyl-activated dextran backbone, coupled with various antigenic determinants derived from different molecules and species.

Career Highlights

Throughout his career, Peter Koefoed has been associated with reputable firms such as Pharmexa A/S and H. Lundbeck A/S. His work in these companies has considerably advanced the development of immunological treatments and vaccines. Koefoed's innovative thinking and his expertise in the domain have facilitated the progress of several groundbreaking projects, solidifying his status as a leading inventor in the pharmaceutical industry.

Collaborations

Peter Koefoed has collaborated with esteemed colleagues, including Klaus Gregorius Nielsen and Peter Birk Rasmussen. These professional associations have played a crucial role in enhancing the collaborative spirit needed for successful innovations in vaccine technology.

Conclusion

Peter Koefoed's contributions to vaccine development underscore the importance of innovation in addressing complex medical challenges. His patents reflect a deep understanding of immunology and a commitment to advancing healthcare through inventive solutions. As continued research progresses, Koefoed's work will likely inspire future developments in the fight against diseases related to amyloid deposition.